Navigation Links
Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study

Phase III trial planned
Abstracts: 2000, 2002

CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of a Phase I/IIa study presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago demonstrate the clinical activity of cilengitide in patients with newly diagnosed glioblastoma – a particularly aggressive form of brain tumor. Cilengitide is a highly selective integrin inhibitor targeting the tumor and its vasculature.

Fifty-two patients with newly diagnosed glioblastoma were treated with cilengitide, combined with a standard regimen of radiotherapy and temozolomide following tumor resection or biopsy. The study reached the predefined primary endpoint with 69% of patients being alive and progression free at six months, and showed a median progression free survival (PFS) of 8.1 months. In a defined patient subgroup with the methylated MGMT gene promoter in the tumor tissue, 91% of patients had six months PFS and the median has not yet been reached. These results are encouraging when compared to the historical control of the EORTC-NCIC phase III trial [overall population: 54% 6 months PFS, median PFS of 6.9 months;(1) methylated MGMT gene promoter subgroup: 69% PFS and 10.3 months median PFS].(2)

Lead investigator Dr. Roger Stupp of the University of Lausanne Hospital in Switzerland, commented: “We are excited by these findings. They demonstrate the potential of cilengitide to make a real difference to the outcome of patients with this aggressive type of brain cancer, where currently available treatment options are limited and prognosis is poor. We look forward to learning more about the benefits of this promising agent in larger patient populations.”

Also presented at ASCO was a Phase IIa randomized multicenter trial, examining two dosing levels of cilengitide monotherapy (500mg and 2000mg) in 81 patients with recurrent gliobl
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
3. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
4. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
5. Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting
6. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
11. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
Post Your Comments:
(Date:10/7/2008).... 7 / Burcon NutraScience,C...ratein(R) and,Supertein(TM) canola protein isolate...r intended use in a variety of food and beverage,a...GRAS through an,independent evaluation by a panel ... toxicology, nutritional sciences, food allergies ...
(Date:10/7/2008)...ct. 7 /- CEL-SCI Corporatio...d into a Material Transfer,Agreement (MTA) with th...IHCC) and the laboratory of Dr. Francesco M. Marin...changes to the tumor microenvironment,caused by CE...e Chief of,the Infectious Disease and Immunogentic...
(Date:10/7/2008)...Colo., Oct. 7 /- A study published in... stem cell self-renewal,reported that InVitria,s ...,human serum albumin) was an effective replacement... article entitled, "The ground state of embryonic ...s used Cellastim as a recombinant,albumin in place...
(Date:10/7/2008)...s., Oct. 7 /- Taligen Therapeutics In... the Company,s pipeline,candidates were presented ...asel, Switzerland. The data highlighted the candid...ent-mediated diseases., "These highlighted presen...nted at the conference, reveal the deep expertise ...
Breaking Medicine Technology:Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths 3502 1World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths 3502 2World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths 3502 3National Award Recognizes Delmarva Foundation and CareFirst BlueCross BlueShield Quality Improvement Efforts 3500 1National Award Recognizes Delmarva Foundation and CareFirst BlueCross BlueShield Quality Improvement Efforts 3500 2Hospital Coalition Says Governors No Fault Bill Signing Provides a Great Protection for Florida Consumers 3498 1Hospital Coalition Says Governors No Fault Bill Signing Provides a Great Protection for Florida Consumers 3498 2Study Author Urges Peers to Stop Using Pain Pumps in the Shoulder Joint as Seasonal Surge in Use Approaches 3496 1Study Author Urges Peers to Stop Using Pain Pumps in the Shoulder Joint as Seasonal Surge in Use Approaches 3496 2Study Author Urges Peers to Stop Using Pain Pumps in the Shoulder Joint as Seasonal Surge in Use Approaches 3496 3
...y 5 /PRNewswire-FirstCall/ -- Nuvelo,Inc. (Nasdaq...(Anticoagulation with rNAPc2 To Help Eliminate MAC...matode anticoagulant protein c2,(rNAPc2) in patien...l data evaluating rNAPc2 in mouse models of colore...echanism of NU172, a,short-acting, direct thrombin...
...USINESS WIRE)--Jul 5, 2007 - Australian,biotechnol...mpletion of apricitabine,s controlled, double blin...nt of its Phase IIb trial.,Patients have now progr...eks 24 to 48) and will continue to receive 800mg,a...atment regime.,The Company expects to release resu...
Other Medicine Technology:Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst,Congress of the International Society on Thrombosis and Haemostasis 2Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst,Congress of the International Society on Thrombosis and Haemostasis 3Avexa's Apricitabine Clinical Trial Update 2
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...s at the University of Siena, researchers found th... alleviating pain felt by children during medical ...n the study, Carlo Belliene and his team from Le S...ldren, aged between 7 and 12, into three groups at...
...boils and pimples severe enough to send people to ... deadly// bacterium that cannot be treated with co...in resistant staphylococcus aureus (MRSA) is found...oft tissue infections in 11 emergency rooms acros...
...ancer” initiative at Roswell Park Cancer Institute...omen’s health //after they are diagnosed with brea...d prevention of cancer recurrence. The comprehens...Chen Hong, PhD, and Christine Ambrosone, PhD, Depa...
...ides affecting how people relate to others, accord...aborative Program of Excellence in Autism compared... 15, with 56 who did not have the condition. It w...sm were found to have more problems with complex t...
Other Medicine News:Health News:Deadly superbug on the rise 2Health News:Study Focuses on Women's Health After Breast Cancer 2Health News:Multiple Parts of the Brain Affected by Autism 2
...eica ASP200 is an advanced smart processor for par...ne histopathology applications. Proven and enhance... smart operating software are the hallmark of the ...ed and the software includes a variety of SMART fe...
The electronic, motorized rotary microtomes are designed for all applications of paraffin, semi-thin (HM 360), and hard specimens in clinical, research, and industrial labs. These instruments display
...eica RM2255 rotary microtome, designed for fully m...bedded specimens, offers a broad application spect...ory. This microtome meets the requirements of user...c microtome for their laboratory. The entire acces...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user.
Medicine Products: